RxDoctor Payments Data

Robert Westrol, MD

Pain Medicine · Greenville, SCNPI 1497796916

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Medtronic at 48.6% of the total. Reporting peaked in 2023 at $1,239 and has fallen 51.2% since, to $605 in 2025.

$5,269in general payments, 2019–2025

Across 121 payments — averaging $43.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$1K
  • SPR Therapeutics, Inc$529
  • Abbott$398
  • Forte Bio-pharma LLC$291
  • Collegium Pharmaceutical, Inc.$220
  • plus $261 from 11 others

What the payments were for

  • Travel & lodging$4048%
  • Food & beverage$4,86592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,269 in reported general payments places this provider in the 65th percentile of 92 pain medicine providers in South Carolina.

See all pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$120,422
Medicare patients
392
Services billed
1,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine53$9,786
BelbucaBuprenorphine Hcl18$8,542
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen189$8,162
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen316$6,536
Xtampza ErOxycodone Myristate13$5,889
Oxycodone Hcl92$1,489
Pregabalin61$1,232
Morphine Sulfate ErMorphine Sulfate50$1,075
Duloxetine Hcl38$371
Gabapentin34$369
Celecoxib27$270
Tramadol Hcl54$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$220$14,43231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 92 pain medicine providers in South Carolina.

Other pain medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →